1GO AS, HYLEK EM, CHANG Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trial translate into clinical practice?[J]. JAMA, 2003, 290( 20 ) : 2685-2692.
2BORIANI G, DIEMBERGER I, BIFFI M, et al. Pharmacological cardioversion of atrial fibrillation: current management and treatment options[J]. Drugs, 2004, 64 (24) : 2741-2762.
3BORIANI G, BIFFI M, DIEMBERGER I, et al. Rate control in atrial fibrillation : choice of treatment and assessment of efficacy [J]. Drugs, 2003, 63(14) : 1489-1509.
4ALLESSIE MA, BOYDEN PA, CAMM AJ, et al. Pathophysiology and prevention of atrial fibrillation[J]. Circulation,2001,103(5) :769-777.
5CHUGH SS, BLACKSHEAR JL, SHEN WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications[J]. J Am Coll Cardiol, 2001,37(2) :371-378.
6HART RG, PEARCE LA, ROTHBART RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators [J]. J Am Coll Cardiol, 2000,35 ( 1 ) : 183-187.
7GUPTA AK, MAHESHWARI A, TRESCH DD, et al. Cardiac arrhythmias in the elderly [J]. Card Electrophysiol Rev, 2002, 6(1-2) : 120-128.
8FUSTER V, RYDEN LE, ASINGER RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practiceand the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences(Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation):developed in collaboration with the North American Society of Pacing and Electrophysiology [J]. Circulation, 2001,104 (17) :2118-2150.
9van der HOOFT CS, HEERINGA J, van HERPEN G, et al.Drug-induced atrial fibrillation [J]. J Am Coil Cardiol, 2004,(11 ) :2117-2124.
10CHAUDHRY GM, HAFFAJEE CI. Antiarrhythmic agents and proarrhythmia[J]. Crit Care Med,2000,28( 10 Suppl ) : 158-164.
